GM2A

GM2 ganglioside activator also known as GM2A is a is_associated_with::protein which in humans is encoded by the GM2A is_associated_with::gene.

Function
The protein encoded by this gene is a small glycolipid transport protein which acts as a substrate specific co-factor for the lysosomal enzyme β-hexosaminidase A. β-hexosaminidase A, together with GM2 ganglioside activator, catalyzes the degradation of the ganglioside GM2, and other molecules containing terminal N-acetyl is_associated_with::hexosamines.

GM2A is a lipid transfer protein that stimulates the enzymatic processing of is_associated_with::gangliosides, and also is_associated_with::T-cell activation through lipid presentation. This protein binds molecules of is_associated_with::ganglioside GM2, extracts them from membranes, and presents them to beta-is_associated_with::hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion to GM3.

It was identified as a member of is_associated_with::ML domain family of proteins involved in is_associated_with::innate immunity and is_associated_with::lipid metabolism in the SMART database. .

Regulation
In melanocytic cells GM2A gene expression may be regulated by MITF.

Clinical significance
Mutations in this gene, inherited in an is_associated_with::autosomal recessive pattern, result in is_associated_with::GM2-gangliosidosis, AB variant, a rare GM2 gangliosidosis that has symptoms and pathology identical with is_associated_with::Tay-Sachs disease and is_associated_with::Sandhoff disease.

GM2A mutations are rarely reported, and the cases that are observed often occur with is_associated_with::consanguineous parents or in genetically isolated populations.

Because AB variant is so rarely diagnosed, even in infants, it is likely that most mutations of GM2A are fatal in the fetus in is_associated_with::homozygotes and is_associated_with::genetic compounds, and thus are never observed clinically.